BridgeBio Oncology Therapeutics, Inc. (BBOT) — Financial Flexibility Index
BridgeBio Oncology Therapeutics, Inc. (BBOT) has a Financial Flexibility Index of -1.12x as of December 2025. Free cash flow of $-41.91 Million (operating CF $-42.23 Million minus capex $320.00K) represents -1% of total liabilities ($37.28 Million). Also explore BBOT shareholders equity momentum to track the company's year-over-year net asset growth rate.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
BridgeBio Oncology Therapeutics, Inc. Financial Flexibility Index (2023–2025)
Historical Financial Flexibility Index trend for BridgeBio Oncology Therapeutics, Inc. across 3 annual periods. Check asset resilience ratio of BridgeBio Oncology Therapeutics, Inc. to evaluate the company's liquid asset resilience ratio.
Annual Financial Flexibility Index for BridgeBio Oncology Therapeutics, Inc. (2023–2025)
Year-by-year free cash flow to debt coverage for BridgeBio Oncology Therapeutics, Inc.. For the full company profile including market capitalisation, see BBOT company net worth.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -3.04x | $-113.29 Million | $-113.89 Million | $37.28 Million | ▼ -2326.1% |
| 2024 | -0.13x | $-714.82K | $-763.82K | $5.71 Million | ▲ +99.9% |
| 2023 | -130.31x | $-51.66 Million | $-52.08 Million | $396.46K | — |